中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 7
Jul.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(7): 1650-1653

Clinical epidemiology and pathological features of cryptogenic cirrhosis

DOI: 10.3969/j.issn.1001-5256.2022.07.036

  • Department of Infectious Diseases, The First Hospital of Shanxi Medical University, Taiyuan 030001, China

Research funding:

Key R & D Projects of Department of Science and Technology of Shanxi Province (201903D421056)

More Information
  • Corresponding author: ZHANG Liaoyun, zlysgzy@163.com(ORCID: 0000-0002-7666-7368)
  • Received Date: 2022-01-27
  • Accepted Date: 2022-03-28
  • Published Date: 2022-07-20
    Abstract
  • Cryptogenic cirrhosis (CC), also known as "unexplained liver cirrhosis", refers to liver cirrhosis in some patients that cannot be explained with known causes, and CC accounts for about 5%-10% of all liver cirrhosis cases in clinical practice. This article reviews the research advances in the clinical epidemiology of CC, including etiology, clinical features, outcome, and pathological features, in order to expand the thinking of clinical diagnosis and treatment and help with clinical diagnosis.

     

    • FullText(HTML)
  • loading
    • References(41)
  • [1]
    KANG JH, MATSUI T. Changing etiology in liver cirrhosis in Sapporo, Japan[J]. Euroasian J Hepatogastroenterol, 2018, 8(1): 77-80. DOI: 10.5005/jp-journals-10018-1266.
    [2]
    SHAN S, ZHAO LH, MA H, et al. Definition, etiology, and epidemiology of liver cirrhosis[J]. J Clin Hepatol, 2021, 37(1): 14-16. DOI: 10.3969/j.issn.1001-5256.2021.01.003.

    单姗, 赵连晖, 马红, 等. 肝硬化的定义、病因及流行病学[J]. 临床肝胆病杂志, 2021, 37(1): 14-16. DOI: 10.3969/j.issn.1001-5256.2021.01.003.
    [3]
    WANG XZ, LIU XF. Etiology and complications of liver cirrhosis: an clinical analysis of 2041 cases[J]. Zhejiang Med J, 2017, 39(1): 37-39. DOI: 10.12056/j.issn.1006-2785.2017.39.01.2016-1510.

    王秀珍, 刘雪峰. 2041例肝硬化病因及并发症分析[J]. 浙江医学, 2017, 39(1): 37-39. DOI: 10.12056/j.issn.1006-2785.2017.39.01.2016-1510.
    [4]
    XU ZJ, ZHONG Y, LIU J, et al. Analysis of the characteristics of 58 cases of cryptogenic liver cirrhosis in Shanghai[J]. J Clin Hepatol, 2010, 26(3): 264-266. DOI: 10.3969/j.issn.1001-5256.2010.03.014.

    徐正婕, 钟妍, 刘娇, 等. 上海地区58例隐源性肝硬化特点分析[J]. 临床肝胆病杂志, 2010, 26(3): 264-266. DOI: 10.3969/j.issn.1001-5256.2010.03.014.
    [5]
    RINALDI L, NASCIMBENI F, GIORDANO M, et al. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis[J]. World J Gastroenterol, 2017, 23(8): 1458-1468. DOI: 10.3748/wjg.v23.i8.1458.
    [6]
    YOUNOSSI ZM, BLISSETT D, BLISSETT R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe[J]. Hepatology, 2016, 64(5): 1577-1586. DOI: 10.1002/hep.28785.
    [7]
    SETIAWAN VW, STRAM DO, PORCEL J, et al. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort[J]. Hepatology, 2016, 64(6): 1969-1977. DOI: 10.1002/hep.28677.
    [8]
    YANG YF. Imaging and pathological diagnosis of cirrhosis with unknown pathogen[J]. Chin J Pract Intern Med, 2019, 39(6): 501-505. DOI: 10.19538/j.nk2019060105.

    杨永峰. 不明原因肝硬化的影像和病理学诊断[J]. 中国实用内科杂志, 2019, 39(6): 501-505. DOI: 10.19538/j.nk2019060105.
    [9]
    ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
    [10]
    CZAJA AJ. Cryptogenic chronic hepatitis and its changing guise in adults[J]. Dig Dis Sci, 2011, 56(12): 3421-3438. DOI: 10.1007/s10620-011-1769-9.
    [11]
    CLARK JM, DIEHL AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis[J]. JAMA, 2003, 289(22): 3000-3004. DOI: 10.1001/jama.289.22.3000.
    [12]
    MOHAMMED OK, MAHADEVA S. Clinical outcomes of cryptogenic compared with non-cryptogenic cirrhosis: A retrospective cohort study[J]. J Gastroenterol Hepatol, 2015, 30(9): 1423-1428. DOI: 10.1111/jgh.12978.
    [13]
    O'LEARY JG, LANDAVERDE C, JENNINGS L, et al. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants[J]. Clin Gastroenterol Hepatol, 2011, 9(8): 700-704. e1. DOI: 10.1016/j.cgh.2011.04.007.
    [14]
    POONAWALA A, NAIR SP, THULUVATH PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study[J]. Hepatology, 2000, 32(4 Pt 1): 689-692. DOI: 10.1053/jhep.2000.17894.
    [15]
    TELLEZ-AVILA FI, SANCHEZ-AVILA F, GARCÍA-SAENZ-DE-SICILIA M, et al. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis[J]. World J Gastroenterol, 2008, 14(30): 4771-4775. DOI: 10.3748/wjg.14.4771.
    [16]
    THULUVATH PJ, KANTSEVOY S, THULUVATH AJ, et al. Is cryptogenic cirrhosis different from NASH cirrhosis?[J]. J Hepatol, 2018, 68(3): 519-525. DOI: 10.1016/j.jhep.2017.11.018.
    [17]
    CARROZZO R, HIRANO M, FROMENTY B, et al. Multiple mtDNA deletions features in autosomal dominant and recessive diseases suggest distinct pathogeneses[J]. Neurology, 1998, 50(1): 99-106. DOI: 10.1212/wnl.50.1.99.
    [18]
    TWEEZER-ZAKS N, DORON-LIBNER A, WEISS P, et al. Familial Mediterranean fever and cryptogenic cirrhosis[J]. Medicine (Baltimore), 2007, 86(6): 355-362. DOI: 10.1097/MD.0b013e31815be056.
    [19]
    CHOWDHARY VR, CROWSON CS, POTERUCHA JJ, et al. Liver involvement in systemic lupus erythematosus: case review of 40 patients[J]. J Rheumatol, 2008, 35(11): 2159-2164. DOI: 10.3899/jrheum.080336.
    [20]
    IANNELLO S, BOSCO P, CAMUTO M, et al. A mild form of Alstrom disease associated with metabolic syndrome and very high fasting serum free fatty acids: two cases diagnosed in adult age[J]. Am J Med Sci, 2004, 327(5): 284-288. DOI: 10.1097/00000441-200405000-00031.
    [21]
    BADANO JL, MITSUMA N, BEALES PL, et al. The ciliopathies: an emerging class of human genetic disorders[J]. Annu Rev Genomics Hum Genet, 2006, 7: 125-148. DOI: 10.1146/annurev.genom.7.080505.115610.
    [22]
    BAY L, CANERO VELASCO C, CIOCCA M, et al. Liver disease and dyslipidemia as a manifestation of lysosomal acid lipase deficiency (LAL-D). Clinical and diagnostic aspects, and a new treatment. An update[J]. Arch Argent Pediatr, 2017, 115(3): 287-293. DOI: 10.5546/aap.2017.eng.287.
    [23]
    DEHGHANI SM, IMANIEH MH, HAGHIGHAT M, et al. Etiology and complications of liver cirrhosis in children: report of a single center from southern iran[J]. Middle East J Dig Dis, 2013, 5(1): 41-46.
    [24]
    PINTO RB, SCHNEIDER AC, da SILVEIRA TR. Cirrhosis in children and adolescents: An overview[J]. World J Hepatol, 2015, 7(3): 392-405. DOI: 10.4254/wjh.v7.i3.392.
    [25]
    MAJUMDAR K, SAKHUJA P, PURI AS, et al. Coeliac disease and the liver: spectrum of liver histology, serology and treatment response at a tertiary referral centre[J]. J Clin Pathol, 2018, 71(5): 412-419. DOI: 10.1136/jclinpath-2017-204647.
    [26]
    JOSHI A, FALODIA S, KUMAR N, et al. Prevalence of celiac disease among pediatric patients with cryptogenic cirrhosis and effect of gluten-free-diet[J]. Indian J Gastroenterol, 2018, 37(3): 243-247. DOI: 10.1007/s12664-018-0857-6.
    [27]
    MOROTTI RA, SUCHY FJ, MAGID MS. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings[J]. Semin Liver Dis, 2011, 31(1): 3-10. DOI: 10.1055/s-0031-1272831.
    [28]
    BYRON D, MINUK GY. Clinical hepatology: profile of an urban, hospital-based practice[J]. Hepatology, 1996, 24(4): 813-815. DOI: 10.1002/hep.510240410.
    [29]
    GREEVE M, FERRELL L, KIM M, et al. Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes[J]. Hepatology, 1993, 17(4): 593-598. DOI: 10.1002/hep.1840170411.
    [30]
    BELLE SH, BERINGER KC, DETRE KM. An update on liver transplantation in the United States: recipient characteristics and outcome[J]. Clin Transpl, 1995: 19-33.
    [31]
    SOOKOIAN S, PIROLA CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review[J]. J Hepatol, 2008, 49(4): 600-607. DOI: 10.1016/j.jhep.2008.06.012.
    [32]
    WONG RJ, AGUILAR M, CHEUNG R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States[J]. Gastroenterology, 2015, 148(3): 547-555. DOI: 10.1053/j.gastro.2014.11.039.
    [33]
    GOLABI P, BUSH H, STEPANOVA M, et al. Liver Transplantation (LT) for cryptogenic cirrhosis (CC) and nonalcoholic steatohepatitis (NASH) cirrhosis: data from the scientific registry of transplant recipients (SRTR): 1994 to 2016[J]. Medicine (Baltimore), 2018, 97(31): e11518. DOI: 10.1097/MD.0000000000011518.
    [34]
    YOUNOSSI Z, STEPANOVA M, SANYAL AJ, et al. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options[J]. J Hepatol, 2018, 69(6): 1365-1370. DOI: 10.1016/j.jhep.2018.08.013.
    [35]
    AYATA G, GORDON FD, LEWIS WD, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation[J]. Hum Pathol, 2002, 33(11): 1098-1104. DOI: 10.1053/hupa.2002.129419.
    [36]
    ARGO CK, NORTHUP PG, AL-OSAIMI AM, et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis[J]. J Hepatol, 2009, 51(2): 371-379. DOI: 10.1016/j.jhep.2009.03.019.
    [37]
    CALDWELL SH, LEE VD, KLEINER DE, et al. NASH and cryptogenic cirrhosis: a histological analysis[J]. Ann Hepatol, 2009, 8(4): 346-352. DOI: 10.1016/S1665-2681(19)31748-X
    [38]
    POWELL EE, COOKSLEY WG, HANSON R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years[J]. Hepatology, 1990, 11(1): 74-80. DOI: 10.1002/hep.1840110114.
    [39]
    ABDELMALEK M, LUDWIG J, LINDOR KD. Two cases from the spectrum of nonalcoholic steatohepatitis[J]. J Clin Gastroenterol, 1995, 20(2): 127-130. DOI: 10.1097/00004836-199503000-00011.
    [40]
    NALBANTOGLU I, JAIN D. Cryptogenic cirrhosis: Old and new perspectives in the era of molecular and genomic medicine[J]. Semin Diagn Pathol, 2019, 36(6): 389-394. DOI: 10.1053/j.semdp.2019.07.003.
    [41]
    CALDWELL SH, OELSNER DH, IEZZONI JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease[J]. Hepatology, 1999, 29(3): 664-669. DOI: 10.1002/hep.510290347.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (954) PDF downloads(95) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return